Overview on Rare Congenital Bleeding Disorders and Epidemiological Data from the German Haemophilia Registry (DHR) and a Survey in Germany, Austria, and Switzerland
Hämostaseologie · 01.10.2025 · 45 (05) · 378-389
DOI: 10.1055/a-2681-4611 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.10.2025. Verfasst von Katharina Holstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Center Schleswig-Holstein, Institute for Clinical Chemistry, Coagulation Centre, Kiel, Germany. Hauptthemen laut MEDLINE: Registries, Hemophilia A, Rare Diseases. Die Arbeit nennt 62 Literaturangaben.
Abstract (Originalsprache)
Rare bleeding disorders (RBDs), defined as hereditary coagulation factor deficits other than haemophilia, are characterized by a heterogenous clinical phenotype ranging from life-threatening bleeding to thrombosis. There are uncertainties concerning treatment intensity and levels needed to achieve haemostasis, and epidemiological data from Germany, Austria, and Switzerland (GTH region) are scarce. We performed a narrative literature review, focusing on bleeding phenotype and thrombotic risk. Epidemiologic data, including adults and children, and general treatment approaches have been collected via an online survey among GTH haemophilia centres (all categories) and the general information service of the German national registry (Deutsches Hämophilieregister, DHR). We provided an overview on RBDs, revealing that especially in FV, FVII, and FXI deficiencies, the correlation between factor levels and bleeding phenotype is poor. A thrombotic risk needs to be considered in FVII deficiency and afibrinogenaemia or dysfibrinogenaemia. The survey was completed by 34 centres from Germany, Austria, and Switzerland, and compared with 137 centres reporting data to the DHR. FVII deficiency was confirmed to be the most frequent, and FII deficiency was the rarest RBD in this region. For treatment, single factor concentrates were preferred over multifactor concentrates or plasma, and tranexamic acid was often part of the treatment. Approximately 30, 40, and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University Medical Center Schleswig-Holstein, Institute for Clinical Chemistry, Coagulation Centre, Kiel, Germany.
- Werlhof-Institut MVZ, Hannover, Germany.
- MVZ IMD GmbH, IMD Blood Coagulation Center Hochtaunus, Bad Homburg, Germany.
- DKD Helios Klinik Wiesbaden, Center for Internal Medicine, Haemostaseology, Germany.
- MVZ Labor Dr. Reising-Ackermann und Kollegen, Leipzig, Germany.
- HämoZentrum Dr. Wermes, Hildesheim, Germany.
Zitieren
APA
Holstein, K., Gutensohn, K., Alesci, R. S., Krause, M., Scholz, U., Wermes, C., & Halimeh, S. (2025). Overview on Rare Congenital Bleeding Disorders and Epidemiological Data from the German Haemophilia Registry (DHR) and a Survey in Germany, Austria, and Switzerland. Hämostaseologie, 45(05), 378-389. https://doi.org/10.1055/a-2681-4611
Vancouver
Holstein K, Gutensohn K, Alesci RS, Krause M, Scholz U, Wermes C, et al. Overview on Rare Congenital Bleeding Disorders and Epidemiological Data from the German Haemophilia Registry (DHR) and a Survey in Germany, Austria, and Switzerland. Hämostaseologie. 2025;45(05):378-389. doi:10.1055/a-2681-4611
BibTeX
@article{Holstein2025,
author = {Holstein, Katharina and Gutensohn, Kai and Alesci, Rosa Sonja and Krause, Manuela and Scholz, Ute and Wermes, Cornelia and Halimeh, Susan},
title = {Overview on Rare Congenital Bleeding Disorders and Epidemiological Data from the German Haemophilia Registry (DHR) and a Survey in Germany, Austria, and Switzerland},
journal = {Hämostaseologie},
year = {2025},
volume = {45},
number = {05},
pages = {378--389},
doi = {10.1055/a-2681-4611}
}
EUVIMED